A recent General Practice digest,
as sent to subscribers

Study Type: Narrative review

Key Question: What are the current advances and future directions in drug treatments for Alzheimer's disease beyond amyloid-targeting therapies?

Key Findings:

• Anti-amyloid beta therapies have demonstrated clinical efficacy and gained licensing in several countries, though amyloid-related imaging abnormalities remain a key safety concern
• Cognitive decline continues after amyloid clearance, suggesting amyloid-independent pathological mechanisms drive disease progression
• Future treatment approaches are shifting toward combination therapies targeting multiple pathways including tau aggregation, neuroinflammation, synaptic loss, and metabolic dysfunction

Clinical Relevance: UK GPs should understand that Alzheimer's treatment is evolving beyond single-target approaches, with implications for patient counselling about emerging therapies and potential referral pathways as multimodal treatments become available through NHS specialist services.

Limitations: As a narrative review, this does not provide systematic evaluation of treatment efficacy or safety data.

Study Type: Population-based adoption-discordant sibling comparison study

Key Question: Does early adoption into favourable home environments reduce psychosocial risks in children from at-risk families and provide intergenerational benefits?

Key Findings:

• Adopted siblings showed significantly better outcomes than non-adopted siblings: lower psychiatric disorders (29.8% vs 36.1%), criminal convictions (26.1% vs 34.0%), and social welfare dependency (37.8% vs 48.5%)
• Adopted individuals had higher intelligence scores (4.5 vs 3.8) and university attendance rates (26.0% vs 15.2%)
• Benefits extended to the next generation, with offspring of adopted individuals showing modestly better psychosocial functioning (29.6% vs 32.3% psychiatric disorders)

Clinical Relevance: Demonstrates that early environmental interventions can break cycles of intergenerational disadvantage, supporting UK policy emphasis on early intervention and social determinants of health in primary care practice.

Limitations: Observational design cannot fully eliminate confounding factors that might influence both adoption decisions and outcomes.

Study Type: Interrupted time series analysis

Key Question: Does implementing a clinical decision support algorithm (CEX-HScore) in GP software improve COPD exacerbation detection and specialist referrals in Italian primary care?

Key Findings:

• No significant change in overall COPD exacerbation rates or pulmonologist referrals following algorithm implementation
• Among newly diagnosed COPD patients, coding accuracy for exacerbations improved by 45% per month (P < 0.001) post-implementation
• The algorithm appeared to enhance documentation rather than detection of actual clinical events

Clinical Relevance: Clinical decision support tools may improve coding accuracy for COPD exacerbations in newly diagnosed patients, potentially relevant for UK practices implementing similar digital health interventions under NHS digitisation initiatives.

Limitations: Short follow-up period (6 months post-implementation) limits assessment of longer-term clinical effectiveness and broader population impact.

Study Type: Cohort study (implementation evaluation)

Key Question: How feasible and acceptable is implementing the SPARK tool for systematic collection of social determinants data in primary care settings?

Key Findings:

• Strong patient acceptability: 90.5% found the 20-question tool clear and easy to complete, with 84.5% reporting positive experiences
• High provider acceptance: 96.7% of clinic staff found the tool useful, though only 81.8% had positive experiences
• Implementation challenges centred on resource allocation and workflow integration, with clinics suggesting adaptations to collection methods and personnel support

Clinical Relevance: This provides practical evidence for UK practices considering systematic social determinants screening, particularly relevant given NHS focus on addressing health inequalities and social prescribing initiatives.

Limitations: Single cohort design without control group limits ability to assess comparative effectiveness or longer-term sustainability outcomes.

Study Type: Cross-sectional analysis of prospective cohort data

Key Question: How does state-level structural racism affect cardiovascular health among Black and White adults in the United States?

Key Findings:

• Black participants had significantly lower cardiovascular health scores than White participants (56 vs 64 on Life's Essential 8 scale, p<0.001)
• Black participants in high structural racism states had 12-41% higher odds of poor cardiovascular health across multiple measures (unemployment OR 1.41, residential segregation OR 1.39, education OR 1.37)
• White participants in high structural racism states also had increased odds of poor cardiovascular health, but for fewer measures (12-22% higher odds)

Clinical Relevance: This demonstrates how structural inequalities beyond individual risk factors contribute to cardiovascular health disparities, informing GP understanding of social determinants affecting Black patients' cardiovascular risk in similar socioeconomic contexts.

Limitations: Cross-sectional design cannot establish causality between structural racism measures and cardiovascular health outcomes.

Study Type: Narrative review

Key Question: How can health systems effectively integrate health-related social needs (HRSN) screening into diabetes care to address health inequities?

Key Findings:

• Analysis of 24 implementation studies identified five key barriers: inconsistent triage processes, fragile clinical-community partnerships, weak feedback mechanisms, technology-workflow misalignment, and inadequate equity accountability
• Current approaches often identify social needs through screening but fail to ensure follow-up or resolution, creating fragmented care systems
• Effective integration requires end-to-end approaches linking screening, triage, referral, and feedback within equity-focused care models

Clinical Relevance: Relevant for UK GPs implementing social prescribing and addressing health inequalities, particularly given NHS focus on population health and integrated care systems addressing wider determinants of health.

Limitations: As a narrative review, findings may lack systematic methodology and comprehensive evidence synthesis compared to systematic reviews.

Study Type: Cross-sectional analysis

Key Question: How prevalent are atherosclerotic cardiovascular disease risk-enhancing factors (REFs) in primary prevention populations, and do they influence statin prescribing decisions?

Key Findings:

• 77% of adults aged 40-75 without known ASCVD had at least one REF, with 28% having three or more
• Most common REFs were elevated high-sensitivity CRP (49.6%), metabolic syndrome (48.3%), and hypertriglyceridemia (18.9%)
• Having any REF increased odds of statin use by 2.17-fold (95% CI 1.42-3.33), but this association was inconsistent across different ASCVD risk categories

Clinical Relevance: This highlights the challenge UK GPs face when applying QRISK3 and NICE guidance—risk-enhancing factors are highly prevalent but poorly integrated into systematic prescribing decisions for primary prevention.

Limitations: Cross-sectional design cannot establish causality between REF presence and appropriate statin prescribing decisions.

Study Type: Retrospective analysis

Key Question: Do Care Transformation Organization (CTO) partnerships improve care management capabilities in primary care practices participating in Maryland's Primary Care Program?

Key Findings:

• CTO partnerships providing 30% or 50% of care management services were associated with higher comprehensive care management scores (+0.14-0.15 points) compared to practices with no CTO support
• Analysis included 486 primary care practices over 4 years (2020-2023)
• External partnerships enabled practices to access care management services they couldn't provide in-house

Clinical Relevance: This US model demonstrates how external partnerships can enhance care management capacity in smaller or resource-limited practices, potentially informing PCN development and Primary Care Network support structures in the NHS.

Limitations: The modest effect size and lack of patient outcome data limit assessment of clinical impact.